Bio-Rad Laboratories, Inc.Class A (BIO) Stock Analysis
Market Closed
Sector: Technology · Industry: Laboratory Analytical Instruments
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, growth, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation42/100 · Weak
- P/E vs own history (95th pct)0/25
- FCF yield (3.5%)12/25
- P/S (3.9x)20/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (-3.0%)0/25
- Net income CAGR (-35.0%)0/25
- EPS CAGR 5Y (-33.3%)0/25
- Fwd implied growth (54.0%)25/25
- Profitability18/100 · Weak
- ROIC (-9.4%)0/25
- ROE (2.5%)5/25
- Net margin (6.5%)13/25
- Operating margin (-28.0%)0/25
- Financial Health75/100 · Strong
- Altman Z (3.25)25/25
- Current ratio (3.21)25/25
- Interest coverage (-56.1x)0/25
- Net cash / debt (Net cash)25/25
- Quality35/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (-2.35)20/25
- FCF conversion (n/a)0/25
- Margin stability (σ 158.8%)0/25
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. Show more
In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Headquarters: HERCULES, CA · Employees: 7,450 · Website ↗
Analyst Consensus
BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 21, 2026
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-05-13-550 sh2026-05-11
- SellOption exercise · filed 2026-04-28-186 sh2026-04-24
- SellTax withholding · filed 2026-04-28-77 sh2026-04-24
- BuyOption exercise · filed 2026-04-28+186 sh2026-04-24
- SellOption exercise · filed 2026-04-28-1078 sh2026-04-24
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
42D+P/E (TTM)60.3xD
Grade D: Exp.Price / TTM EPS (own statements) — vs own 5Y history: 2.4x–62.3x · 95th pct
P/FCF28.8xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.5%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: 1.0%–5.9% · 68th pct
P/S (TTM)3.90xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.4x–8.4x · 59th pct
EV/EBITDA230.2xD
Grade D: Exp.Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales4.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E39.1xD
Grade D: Exp.Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.47xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
18EROIC-9.4%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE2.5%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA2.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.5%C
Grade C: AvgNet Income / Revenue
Operating Margin-28.0%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin51.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin13.8%C
Grade C: AvgFCF / Revenue
True FCF Margin13.8%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
75B+Altman Z-Score3.25A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.21xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.92xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-56.1xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.0xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.12xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.95xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Growth
25ERevenue CAGR-3.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-35.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-33.3%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Forward Growth54.0%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-10.7%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Quality
3/10 Loss Years35DPiotroski F-Score5/9C
Grade C: AvgFinancial strength 0–9. >7 Strong
Beneish M-Score-2.35A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability158.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue5.9%C
Grade C: AvgTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.24xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Per Share
EPS (TTM)$6.26
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$57.08
Cash & short-term investments per share (Finnhub)
Book Value / Share$276.16
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$802.90M
Total debt obligations (short + long term)
Cash & Equiv.$1.56B
Cash and short-term investments
Net Debt$-761.80MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$6.85B
Shareholders' equity (book value)
Asset / Liability3.33xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.09B
Current Market Capitalization
Beta1.08B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
BIO ponúka excelentnú finančnú stabilitu s nulovým dlhom, no jej investičnú atraktivitu tlmí slabá profitabilita a priemerný 3,5-percentný výnos z voľného cash flow.
Company is effectively debt-free after netting cash. · Current P/E of 60.3x sits at the 95th percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 22, 2026
Key Insights: Bio-Rad Laboratories, Inc.Class A (BIO)
Composite verdict for Bio-Rad Laboratories, Inc.Class A: BIO ponúka excelentnú finančnú stabilitu s nulovým dlhom, no jej investičnú atraktivitu tlmí slabá profitabilita a priemerný 3,5-percentný výnos z voľného cash flow.. Piotroski F-Score of 5/9 indicates mixed fundamentals for Bio-Rad Laboratories, Inc.Class A. Altman Z-Score of 3.25 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.35 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -3%), which weighs on the growth outlook.
- Company is effectively debt-free after netting cash.
- Interest coverage of -56.1× leaves little room for earnings shocks.
- Bio-Rad Laboratories, Inc.Class A posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
See how BIO ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for BIO in the last 30 days.
See BIO move history →Frequently Asked Questions about BIO
Is BIO stock a buy right now?
PreMarketPrice's quantitative model rates Bio-Rad Laboratories, Inc.Class A's financial health at 75/100 — BIO ponúka excelentnú finančnú stabilitu s nulovým dlhom, no jej investičnú atraktivitu tlmí slabá profitabilita a priemerný 3,5-percentný výnos z voľného cash flow.. This is a data-driven snapshot of fundamentals, not investment advice.
Is BIO stock overvalued?
Bio-Rad Laboratories, Inc.Class A trades at a trailing P/E of 60.3 and our valuation score rates it 42/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bio-Rad Laboratories, Inc.Class A report earnings?
No confirmed earnings date is currently scheduled for BIO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bio-Rad Laboratories, Inc.Class A operate in?
Bio-Rad Laboratories, Inc.Class A operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Bio-Rad Laboratories, Inc.Class A do?
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets.
About Bio-Rad Laboratories, Inc.Class A (BIO) Stock
Bio-Rad Laboratories, Inc.Class A (BIO) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. Real-time pricing data for Bio-Rad Laboratories, Inc.Class A is available on this page with a market capitalization of $10.1 billion. The financial health score for BIO is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BIO stock.
BIO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bio-Rad Laboratories, Inc.Class A (BIO) across multiple dimensions:
- Pre-market price & movement: Real-time BIO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BIO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bio-Rad Laboratories, Inc.Class A across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BIO.
- Sector peers: Compare BIO against 10 other technology stocks on key financial metrics.
Is BIO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bio-Rad Laboratories, Inc.Class A (BIO) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bio-Rad Laboratories, Inc.Class A (BIO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.